《第四批鼓励仿制药品目录》发布 透析、助眠、优生有新盼

Core Viewpoint - The National Health Commission of China, in collaboration with various governmental departments, has released the "Fourth Batch of Encouraged Generic Drug List" to enhance drug supply security and address clinical shortages in the market [1]. Group 1: Drug Selection Criteria - The list includes 21 drug varieties and 47 specifications, focusing on patient treatment needs and addressing gaps in the market [2]. - Priority is given to products with new targets and mechanisms, such as difelikefalin for chronic kidney disease-related itching [2]. - The list also includes drugs recommended in international guidelines, like suvorexant for insomnia, to provide more treatment options [2]. - Products with lower adverse reactions, such as progesterone formulations for assisted reproduction, are prioritized to support fertility policies [2]. - The selection considers accessibility, including products already practiced clinically in China, like deflazacort for Duchenne muscular dystrophy [2]. Group 2: Drug List Details - The list features various drugs, including: - Bexarotene (topical gel, 1%) [3] - Deflazacort (tablets in multiple dosages) [3] - Difelikefalin (injection, 65mcg/1.3mL) [3] - Suvorexant (tablets in multiple dosages) [4] - Progesterone (vaginal gel and suppository) [5] - Additional drugs include midostaurin, opicapone, and others, with various formulations and dosages [4][5][6].